The MHLW (Ministry of Health, Labor and Welfare) introduced an updated approval system that rewards developers with accelerated approvals to encourage clinical development of CAGT products in Japan. IQVIA provides the End-to-End support for CAGT products from pre-clinical to post-marketing in Japan.